Correspondence to ‘Cardiovascular and thromboembolic risks of JAK inhibitors in atopic dermatitis’

Documenti analoghi

• Interpreting the risk of venous thromboembolism with JAK inhibitors in atopic dermatitis
  di: Sheng Li, et al.
  Pubblicazione: (2025)
• Cardiovascular and thromboembolic risks of JAK inhibitors in atopic dermatitis: A global cohort study
  di: Khalaf Kridin, et al.
  Pubblicazione: (2025)
• Response to ‘Cardiovascular and thromboembolic risks of JAK inhibitors in atopic dermatitis: A global cohort study’
  di: Marion Gundelwein, et al.
  Pubblicazione: (2025)
• Thromboembolic risk with JAK inhibitors in atopic dermatitis: Context, caution and clinical relevance
  di: Joseph V. Caravaglio
  Pubblicazione: (2025)
• Disproportionate quality of life decline and unaddressed limitations in amlitelimab atopic dermatitis trial
  di: Shiuan‐Chih Chen, et al.
  Pubblicazione: (2025)